TNFAIP8L1 (tumor necrosis factor-alpha-induced protein 8-like 1, also called TIPE1) is a member of the TNFAIP8 family that functions as a negative regulator of mTOR activity 1. In renal tubular epithelial cells, TNFAIP8L1 disrupts mitochondrial homeostasis by promoting ubiquitination and proteasomal degradation of prohibitin 2 (PHB2), a critical mitophagy receptor 2. This degradation of PHB2 impairs mitophagy and increases mitochondrial reactive oxygen species, contributing to tubular damage and diabetic nephropathy progression 2. Regarding cancer relevance, pan-cancer analysis demonstrates that TNFAIP8L1 expression is significantly elevated in 15 cancer types and reduced in 9 others, correlating with distinct prognostic outcomes 3. TNFAIP8L1 expression associates with cancer-associated fibroblasts and immune-related gene expression patterns across multiple malignancies 3. Additionally, specific TNFAIP8L1 polymorphisms show protective associations against certain cancers; notably, the rs1060555 variant demonstrates a protective effect against cervical cancer risk 45. TNFAIP8L1 transcription is upregulated in inflammatory conditions including idiopathic multicentric Castleman disease-TAFRO/NOS subtypes, suggesting involvement in cytokine storm pathways 6. Clinically, TNFAIP8L1 represents a potential therapeutic target in diabetic nephropathy and may inform cancer prognosis assessment and treatment strategies across diverse tumor types.